Latest News in the pharma Industry

Policy & Regulation

FDA removes clinical hold on CEL-SCI’s Phase III head & neck cancer trial

FDA removes clinical hold on CEL-SCI’s Phase III head & neck cancer trial

14 Aug 2017

The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.

Read more 
FDA approves liposome-encapsulated combination of daunorubicin-cytarabine for adults with AML

FDA approves liposome-encapsulated combination of daunorubicin-cytarabine for adults with AML

13 Aug 2017

Vyxeos represents the first new chemotherapy advance in more than 40 years for these adults with AML.

Read more 
NICE recommends Erbitux in combination with chemotherapy for the treatment of head and neck cancer

NICE recommends Erbitux in combination with chemotherapy for the treatment of head and neck cancer

9 Aug 2017

Decision secures access to Erbitux for new patients in England with oral cavity tumours.

Read more 
Mylan receives tentative approval for TLD under PEPFAR

Mylan receives tentative approval for "TLD" under PEPFAR

7 Aug 2017

Mylan's TLD is the first fixed-dose combination of its kind to be offered to patients being treated for HIV/AIDS.

Read more 
Insanitary conditions bring Isomeric Pharmacy Solutions to a halt

Insanitary conditions bring Isomeric Pharmacy Solutions to a halt

6 Aug 2017

Federal judge enters consent decree against outsourcing facility Isomeric Pharmacy Solutions.

Read more 
AbbVie's Mavyret receives FDA approval for the treatment of chronic hepatitis C

AbbVie's Mavyret receives FDA approval for the treatment of chronic hepatitis C

6 Aug 2017

FDA approval is supported by an overall 98% cure rate in patients who received the recommended duration of treatment .

Read more 
NICE approves Abraxane for pancreatic cancer

NICE approves Abraxane for pancreatic cancer

6 Aug 2017

Life-extending pancreatic cancer medicine to be made available immediately on the NHS.

Read more 
FDA grants Genentech’s Alecensa Priority Review

FDA grants Genentech’s Alecensa Priority Review

3 Aug 2017

Designation given for initial treatment of people with ALK-positive lung cancer.

Read more 
BMS receives FDA approval for Opdivo Injection for metastatic colorectal cancer

BMS receives FDA approval for Opdivo Injection for metastatic colorectal cancer

3 Aug 2017

Approval based on CheckMate -142, in which Opdivo demonstrated an objective response rate of 28% among patients who received prior treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Read more 
Amgen submits sBLA for Prolia in glucocorticoid-induced osteoporosis

Amgen submits sBLA for Prolia in glucocorticoid-induced osteoporosis

31 Jul 2017

Results from the Phase III study included in the sBLA submission showed that treatment with Prolia for 12 months led to statistically significant greater gains in BMD at the lumbar spine and total hip compared to risedronate.

Read more 
BMS's Orencia receives second EC approval in less than a year

BMS's Orencia receives second EC approval in less than a year

26 Jul 2017

New approval for treatment of active psoriatic arthritis (PsA).

Read more 
New research highlights lack of confidence in serialization preparations

New research highlights lack of confidence in serialization preparations

25 Jul 2017

40% of industry professionals admit they are not clear about the global requirements for serialization.

Read more